Merck to sell some ophthalmology assets for at least $600M

|About: Merck & Co Inc. (MRK)|By:, SA News Editor

Merck (MRK) has agreed to sell some ophthalmology products to Santen Pharmaceutical (SNPHY) for $600M upfront plus milestone payments.

The deal covers Japan, as well as "key markets" in Europe and Asia Pacific, with the products generating $400M in annual sales in those regions.

The transaction follows Merck's sale of its U.S. ophthalmology business to Akorn Pharmaceuticals.

Merck will continue to sell ophthalmology products in various markets, including Latin America, Canada, Australia, and EMEA. (PR)